On 10 September 2024, Eli Lilly announced that it met the primary endpoints for A1C (blood glucose measurement) reduction in the QWINT-2 (type 2 diabetes) and QWINT-5 (type 1 diabetes) trials for once weekly insulin efsitora alfa. The results were simultaneously published in The New England Journal of Medicine and The Lancet on 10 September and, on the same day, were presented at the European Association for the Study of Diabetes.
Novo Nordisk’s once-weekly insulin icodec, supplied under the brand name Awiqli®, was recommended for EU approval on 22 March 2024 and subsequently received EU marketing authorisation for treating diabetes in May 2024. Awiqli® has been approved in Switzerland and Canada (March 2024), Japan and Australia (June 2024) and was endorsed in China in June 2024 for type 2 diabetes.